Retatrutide

GLP-1 / GIP / GCG Receptor Triagonist  |  CAS: 2381015-17-4

Compound Overview

Retatrutide (LY3437943) is a synthetic peptide triagonist targeting glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCG) receptors simultaneously. Structural modifications extend plasma half-life relative to endogenous peptides, allowing sustained receptor engagement.

Mechanism of Action

Simultaneous agonism at GLP-1, GIP, and GCG receptors produces complementary metabolic effects: GLP-1 activity reduces gastric emptying and appetite signalling; GIP activity modulates insulin sensitivity; GCG receptor engagement promotes hepatic glucose output and thermogenesis. Combined receptor activation creates additive effects on energy expenditure not achievable through single-receptor approaches.

Research Applications

• Triagonist receptor pharmacology in metabolic disease models
• Energy expenditure and lipid oxidation pathway studies
• Comparative analysis against GLP-1 monoagonists and dual agonists
• Appetite regulation and satiety signalling research

Analytical Data

AOD-9604

HGH Fragment 177–191  |  Lipolytic Peptide

Compound Overview

AOD-9604 is a truncated C-terminal fragment of human growth hormone, comprising amino acids 177–191. It retains the lipolytic properties of the full HGH molecule while lacking the domain responsible for insulin-like activity, resulting in a compound with selective adipose tissue effects in research models.

Mechanism of Action

AOD-9604 targets beta-3 adrenergic receptors on adipocytes, stimulating lipolysis and inhibiting lipogenesis. Unlike full-length HGH, it does not significantly affect IGF-1 levels or insulin sensitivity in studied models, making it useful for isolating fat metabolism pathways independent of anabolic or glycaemic confounders.

Research Applications

• Selective lipolysis and adipocyte receptor pharmacology
• Lipogenesis inhibition pathway studies
• Comparative metabolic research against full-length HGH
• Obesity model research without glycaemic interference

Analytical Data

MOTS-c

Mitochondrial-Encoded Peptide  |  16 Amino Acids

Compound Overview

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino-acid peptide encoded within the mitochondrial genome. It is notable as one of the few peptides capable of mitochondria-to-nucleus retrograde signalling, regulating nuclear gene expression in response to metabolic stress.

Mechanism of Action

MOTS-c activates AMP-activated protein kinase (AMPK), a central regulator of cellular energy homeostasis. AMPK activation promotes glucose uptake in skeletal muscle, fatty acid oxidation, and mitochondrial biogenesis. MOTS-c also modulates the folate cycle and methionine metabolism, contributing to its systemic metabolic effects.

Research Applications

• Mitochondrial retrograde signalling studies
• AMPK activation and downstream metabolic pathway research
• Insulin sensitivity and glucose metabolism models
• Exercise mimetic compound research

Analytical Data

5-Amino-1MQ

NNMT Inhibitor  |  Small Molecule

Compound Overview

5-Amino-1-methylquinolinium (5-Amino-1MQ) is a selective, membrane-permeable inhibitor of Nicotinamide N-methyltransferase (NNMT), a cytosolic enzyme involved in energy homeostasis and NAD+ metabolism. NNMT overexpression is associated with adipogenesis and reduced cellular NAD+ availability.

Mechanism of Action

By inhibiting NNMT, 5-Amino-1MQ increases intracellular NAD+ and S-adenosylmethionine (SAM) availability. Elevated NAD+ activates SIRT1, a deacetylase involved in mitochondrial biogenesis and fat oxidation. This pathway differs from stimulant-based thermogenic compounds as it operates at the enzymatic rather than adrenergic level.

Research Applications

• NNMT enzyme inhibition pharmacology
• NAD+ metabolism and SIRT1 activation research
• Adipogenesis and muscle catabolism model studies
• Metabolic rate modulation without CNS stimulation

Analytical Data

BPC-157

Pentadecapeptide  |  15 Amino Acids  |  Gastric Origin

Compound Overview

BPC-157 is a stable synthetic pentadecapeptide derived from a sequence within the human gastric protein BPC. It is notable for resistance to enzymatic degradation, contributing to its stability in research environments. It is among the more extensively studied research peptides in tissue repair models.

Mechanism of Action

BPC-157 promotes angiogenesis by stimulating VEGF expression and upregulating GH receptor sensitivity in target tissues. It modulates nitric oxide synthesis, which contributes to vasodilation and nutrient delivery to areas with limited natural blood supply such as tendons and ligaments. Gut integrity effects appear to involve COX-2 pathway modulation and mucosal protection.

Research Applications

• Tendon and ligament repair models (angiogenesis induction)
• Gastric mucosal protection and gut integrity research
• VEGF and GH receptor upregulation studies
• Nitric oxide pathway modulation research

Analytical Data

TB-500

Thymosin Beta-4 Analog  |  Actin-Binding Peptide

Compound Overview

TB-500 is a synthetic analog of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino-acid protein expressed in most mammalian cells. It corresponds to the actin-binding domain of the full-length protein. Its relatively low molecular weight allows distribution through tissue compartments that larger proteins cannot easily reach.

Mechanism of Action

TB-500 sequesters G-actin monomers, regulating the dynamics of actin polymerisation critical for cell migration. This facilitates movement of endothelial and repair cells toward injury sites. Downstream effects include angiogenesis, inflammatory cytokine modulation, and extracellular matrix remodelling in studied models.

Research Applications

• Actin regulation and cellular migration studies
• Angiogenesis and endothelial repair models
• Inflammatory cytokine modulation research
• Extracellular matrix remodelling studies

Analytical Data

KPV

Lys-Pro-Val  |  Alpha-MSH C-Terminal Tripeptide

Compound Overview

KPV is a C-terminal tripeptide fragment of alpha-Melanocyte-stimulating hormone (α-MSH). It retains the anti-inflammatory properties of the parent peptide while being significantly smaller, which affects its distribution characteristics and receptor binding profile compared to full-length α-MSH.

Mechanism of Action

KPV inhibits NF-κB activation, a central regulator of inflammatory cytokine production. It also demonstrates direct antimicrobial activity by disrupting microbial cell wall integrity. Melanocortin receptor binding (particularly MC1R) contributes to its anti-inflammatory signalling in studied models, including gut epithelial applications.

Research Applications

• NF-κB inhibition and inflammatory cytokine research
• Gut epithelial integrity and IBD models
• Antimicrobial peptide mechanism studies
• Melanocortin receptor pharmacology

Analytical Data

GHK-Cu

Glycyl-L-histidyl-L-lysine Copper Complex  |  Signal Peptide

Compound Overview

GHK-Cu is a naturally occurring copper-binding tripeptide that declines significantly with age. It functions as a pleiotropic signal peptide, capable of modulating a broad range of gene expression related to tissue remodelling, antioxidant defence, and inflammation. Its characteristic deep blue colour upon reconstitution is due to the copper coordination complex.

Mechanism of Action

GHK-Cu activates dermal fibroblasts to increase production of collagen, elastin, and glycosaminoglycans. Gene expression analysis suggests it modulates over 3,000 human genes, including upregulation of antioxidant pathways and downregulation of inflammatory mediators. It also promotes stem cell activation in hair follicle and skin repair models.

Research Applications

• Dermal fibroblast activation and collagen synthesis studies
• Gene expression modulation research (Broad gene array studies)
• Hair follicle stem cell research
• Wound healing and dermal barrier repair models

Analytical Data

Snap-8

Acetyl Octapeptide-3  |  SNARE Complex Modulator

Compound Overview

Snap-8 (Acetyl Octapeptide-3) is a synthetic octapeptide that mimics the N-terminal sequence of SNAP-25, a protein integral to the SNARE complex. It is an extension of the hexapeptide Argireline, developed to improve stability and penetration in topical applications.

Mechanism of Action

By competing for SNAP-25 binding sites within the SNARE complex, Snap-8 partially inhibits the formation of the ternary SNARE complex required for vesicle fusion and acetylcholine release at the neuromuscular junction. The result is a moderate reduction in muscle contraction intensity in targeted facial muscle tissue in studied models.

Research Applications

• SNARE complex inhibition mechanism studies
• Neuromuscular junction acetylcholine release modulation
• Topical delivery and dermal penetration research
• Expression line reduction model studies

Analytical Data

Epitalon

Ala-Glu-Asp-Gly  |  Synthetic Tetrapeptide

Compound Overview

Epitalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from Epithalamin, a natural extract of the bovine pineal gland. It was originally researched by the St. Petersburg Institute of Bioregulation and Gerontology. Most of the published foundational research originates from this institution and associated Russian laboratories.

Mechanism of Action

Epitalon is reported to induce telomerase activity in somatic cells, potentially extending telomere length and delaying cellular senescence. It also modulates pineal gland melatonin secretion and shows effects on neuroendocrine regulation in aged animal models. The mechanism of telomerase induction at the molecular level is not fully characterised.

Research Applications

• Telomerase activity induction and telomere biology research
• Pineal gland function and melatonin regulation studies
• Neuroendocrine ageing model research
• Cellular senescence and longevity pathway investigation

Analytical Data

Semax

ACTH(4–7) Analog  |  Neuropeptide

Compound Overview

Semax is a synthetic heptapeptide analog of ACTH fragments 4–7, developed in Russia and registered there as a pharmaceutical for neurological conditions including stroke recovery and cognitive impairment. It lacks the hormonal activity of full-length ACTH, retaining primarily neuroprotective and neurogenic properties.

Mechanism of Action

Semax increases expression of Brain-Derived Neurotrophic Factor (BDNF) and its receptor TrkB, supporting neuronal survival and synaptic plasticity. It also modulates dopaminergic and serotonergic neurotransmission and demonstrates neuroprotective effects against hypoxia and oxidative stress in studied models. Intranasal delivery achieves direct CNS access via the olfactory pathway.

Research Applications

• BDNF expression and neurotrophin signalling research
• Neuroprotection under hypoxic and excitotoxic conditions
• Dopaminergic and serotonergic modulation studies
• Cognitive function models in neurodegeneration research

Analytical Data

Selank

Tuftsin Analog  |  Anxiolytic Heptapeptide

Compound Overview

Selank is a synthetic heptapeptide analog of the immunomodulatory tetrapeptide Tuftsin, with an additional stabilising peptide sequence. Like Semax, it was developed in Russia and has regulatory status there as a pharmaceutical for anxiety disorders. It is noted for anxiolytic activity without sedation in studied populations.

Mechanism of Action

Selank modulates the metabolism of monoamine neurotransmitters including serotonin and dopamine, and inhibits enkephalin-degrading enzymes, increasing the duration of endogenous opioid peptide activity. It also modulates Interleukin-6 expression, suggesting an immune-brain axis component. GABAergic system interaction has been proposed but is not fully established.

Research Applications

• Anxiolytic mechanism studies without sedative pathway involvement
• Enkephalin metabolism and endogenous opioid system research
• Monoamine neurotransmitter modulation studies
• Immune-brain axis and IL-6 modulation research

Analytical Data

IGF-1 LR3

Insulin-Like Growth Factor-1 Long R3  |  Extended Half-Life Analog

Compound Overview

IGF-1 LR3 is a synthetic analog of human IGF-1, modified at the N-terminus with an arginine substitution at position 3 and a 13-amino-acid extension that prevents binding to IGF-binding proteins (IGFBPs). This modification extends plasma half-life from approximately 20 minutes (native IGF-1) to 20–30 hours, allowing prolonged receptor activation.

Mechanism of Action

IGF-1 LR3 binds the IGF-1 receptor (IGF-1R) with high affinity, activating downstream PI3K/Akt and MAPK/ERK pathways. These pathways regulate satellite cell proliferation (myoblast formation), protein synthesis, and glucose uptake in muscle tissue. The extended half-life means systemic rather than localised receptor engagement.

Research Applications

• Satellite cell proliferation and muscle hyperplasia research
• IGF-1R pathway pharmacology and downstream signalling
• IGFBP interaction and half-life extension mechanism studies
• Anabolic pathway research in muscle tissue models

Analytical Data

PT-141

Bremelanotide  |  Melanocortin Receptor Agonist

Compound Overview

PT-141 (Bremelanotide) is a cyclic heptapeptide analog of alpha-Melanocyte-stimulating hormone (α-MSH). It is an FDA-approved pharmaceutical (Vyleesi) indicated for hypoactive sexual desire disorder in premenopausal women, giving it a clearer regulatory and clinical data profile than most peptides in this class.

Mechanism of Action

PT-141 binds melanocortin receptors MC3R and MC4R in the central nervous system, primarily in the hypothalamus. This CNS-mediated pathway distinguishes it from PDE5 inhibitors, which act peripherally on vascular smooth muscle. MC4R activation in the hypothalamus is associated with modulation of sexual arousal pathways independent of vascular function.

Research Applications

• Central melanocortin receptor (MC3R/MC4R) pharmacology
• Hypothalamic sexual drive pathway research
• CNS vs. peripheral mechanisms in sexual function models
• Melanocortin system and energy homeostasis research

Analytical Data

Melanotan II

alpha-MSH Cyclic Analog  |  Melanocortin Agonist

Compound Overview

Melanotan II is a synthetic cyclic analog of alpha-MSH, developed originally at the University of Arizona. It is a non-selective melanocortin receptor agonist with activity at MC1R, MC3R, MC4R, and MC5R. Unlike PT-141 (which targets MC3R/MC4R selectively), Melanotan II's broader receptor activity produces a wider range of physiological effects in research models.

Mechanism of Action

MC1R agonism stimulates melanocyte production of eumelanin (dark pigment), producing UV-independent skin darkening. MC4R agonism mediates CNS effects on appetite suppression and drive pathways. MC5R activity contributes to exocrine gland effects. The broad receptor profile results in multiple concurrent biological effects that can complicate isolated pathway research.

Research Applications

• Melanogenesis and MC1R-mediated pigmentation research
• Broad melanocortin receptor pharmacology studies
• UV-independent tanning mechanism investigation
• Appetite and energy homeostasis pathway research via MC4R

Analytical Data

The Glow Blend (70mg)

Tri-Compound Fusion  |  GHK-Cu + BPC-157 + TB-500

Compound Overview

The Glow Blend is a pre-combined lyophilised formulation containing 50mg GHK-Cu, 10mg BPC-157, and 10mg TB-500 in a single vial. The three compounds address complementary mechanisms: fibroblast activation and gene expression (GHK-Cu), angiogenesis and tissue repair signalling (BPC-157), and cellular migration and actin regulation (TB-500).

Research Rationale

Combining these three compounds targets dermal and systemic repair through distinct non-overlapping pathways simultaneously. GHK-Cu operates at the gene expression level; BPC-157 operates through growth factor receptor upregulation and VEGF; TB-500 operates through actin dynamics and cellular migration. The combination has not been studied as a formulation in published clinical literature.

Research Applications

• Multi-pathway dermal repair and regeneration research
• Collagen/elastin synthesis combined with angiogenesis studies
• Combined gene expression and structural repair pathway research

Analytical Data

Metabolic Combination A

Retatrutide + AOD-9604  |  Dual Metabolic Pathway

Combination Rationale

This combination pairs a triagonist receptor approach (Retatrutide: GLP-1/GIP/GCG) with a selective peripheral lipolytic agent (AOD-9604: beta-3 adrenergic on adipocytes). The mechanisms are complementary and non-overlapping, targeting appetite and energy expenditure centrally while independently stimulating adipocyte-level fat breakdown.

Restoration Combination A

BPC-157 + TB-500  |  Connective Tissue Repair

Combination Rationale

BPC-157 and TB-500 are among the most co-researched peptide combinations in tissue repair literature. BPC-157 promotes angiogenesis and GH receptor sensitivity at the repair site; TB-500 facilitates cellular migration via actin regulation, enabling repair cells to reach the site efficiently. The two mechanisms are structurally complementary in repair cascade research.

Cognitive Combination A

Semax + Selank  |  Neurotrophic + Anxiolytic

Combination Rationale

Semax and Selank share a common research origin and have been studied in adjacent neurological contexts. Semax addresses BDNF upregulation and neuroprotection; Selank addresses anxiolytic modulation and enkephalin protection. Their mechanisms are distinct, with Semax acting more on neurotrophin pathways and Selank on monoamine and opioid peptide metabolism.

Aesthetic Combination A

GHK-Cu + Snap-8  |  Dermal Remodelling

Combination Rationale

GHK-Cu operates at the gene expression level to increase collagen and elastin synthesis from the dermal foundation. Snap-8 modulates the SNARE complex to reduce neuromuscular contraction intensity at the surface. These are complementary mechanisms targeting structural dermal integrity and surface expression line formation through distinct pathways.

Restoration Combination B

BPC-157 + TB-500 + KPV + GHK-Cu  |  Systemic Repair

Combination Rationale

This four-compound combination addresses tissue repair through structural (BPC-157, TB-500), anti-inflammatory (KPV), and tissue remodelling (GHK-Cu) pathways. Each compound targets a distinct aspect of the repair cascade, with minimal mechanistic overlap. The combination is designed for research contexts where multi-pathway systemic repair modelling is the objective.